Tildrakizumab

替瑞奇珠单抗

Report date: 2025/06/09 15:01:42

Base Information

Drug NameTildrakizumab
Drug Alias NameTildrakizumab-asmn替曲吉珠单抗替卓组单抗替拉珠单抗Ilumetri +[16] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-23 subunit p19 inhibitors
TargetsInterleukin-23 subunit p19
Therapy Area/IndicationsPlaque psoriasisPemphigoid, BullousPsoriasis +[5] 
Global Approved IndicationsPlaque psoriasisPsoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2018/03/20
Country/TerritoryCzechiaBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Kangzhe Biotechnology Co LtdChina Medical System Holdings LtdSun Pharmaceutical Industries Ltd +[6] 
Inactive CompaniesThe Brigham and Women's HospitalVetter Pharma-Fertigung Gmbh & Co KgMerck Sharp & Dohme LLC +[4] 
Active IndicationsPlaque psoriasisPsoriasisArthritis, Psoriatic
Inactive IndicationsPemphigoid, BullousSpondylitis, Ankylosing

Other Information

ATC CodeL04AC17
Related LinksWikipediaDrugBankKEGG